Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis

Journal of Bone and Joint Surgery - American Volume

Volumn 97, Issue 2, 2015, Pages 133-140

  Virdi, Amarjit S ^a   Irish, John ^a   Sena, Kotaro ^b   Liu, Min ^c   Ke, Hua Zhu ^c   McNulty, Margaret A ^d   Sumner, Dale R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c AMGEN INC   (United States)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ANTIBODY; SCLEROSTIN ANTIBODY; TITANIUM; UNCLASSIFIED DRUG; ANTIBODY; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE IMPLANT; BONE MASS; BONE REMODELING; BONE STRENGTH; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); FEMALE; FEMUR; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; TRABECULAR BONE; ANIMAL; BONE DEVELOPMENT; BONE REGENERATION; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; ETIOLOGY; GENETIC MARKER; IMMUNOLOGY; PREVENTION AND CONTROL; PROSTHESIS FAILURE; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; DISEASE MODELS, ANIMAL; FEMALE; GENETIC MARKERS; OSSEOINTEGRATION; OSTEOGENESIS; OSTEOPOROSIS; OVARIECTOMY; PROSTHESIS FAILURE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84921692188     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.N.00654     Document Type: Article

References (51)

1. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg DP, McQuaid D, Moutsatsos IK, Nove J, Wozney JM. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A. 1990 Mar;87(6):2220-4.
2. Sumner DR, Virdi AS. Materials in hip surgery: bioactive coatings for implant fixation. In: Berry DJ, Lieberman JR, editors. Surgery of the hip. New York: Elsevier; 2013. p. 145-156.
3. Moucha CS, Urban RM, Turner TM, Jacobs JJ, Sumner DR. Fixation of implants. In: Shanbhag A, Rubash HE, Jacobs JJ, editors. Joint replacements and bone resorption: pathology, biomaterials and clinical practice. New York: Taylor & Francis; 2006. p. 13-52.
4. Gabet Y, Kohavi D, Voide R, Mueller TL, Müller R, Bab I. Endosseous implant anchorage is critically dependent on mechanostructural determinants of peri-implant bone trabeculae. J Bone Miner Res. 2010 Mar;25(3):575-83.
5. Ross RD, Hamilton JL, Wilson BM, Sumner DR, Virdi AS. Pharmacologic augmentation of implant fixation in osteopenic bone. Curr Osteoporos Rep. 2014 Mar;12(1):55-64.
6. Lingard EA, Mitchell SY, Francis RM, Rawlings D, Peaston R, Birrell FN, McCaskie AW. The prevalence of osteoporosis in patients with severe hip and knee osteoarthritis awaiting joint arthroplasty. Age Ageing. 2010 Mar;39(2):234-9. Epub 2009 Dec 23.
7. Mäkinen TJ, Alm JJ, Laine H, Svedström E, Aro HT. The incidence of osteopenia and osteoporosis in women with hip osteoarthritis scheduled for cementless total joint replacement. Bone. 2007 Apr;40(4):1041-7. Epub 2007 Jan 17.
8. Aro HT, Alm JJ, Moritz N, Mäkinen TJ, Lankinen P. Low BMD affects initial stability and delays stem osseointegration in cementless total hip arthroplasty in women: a 2-year RSA study of 39 patients. Acta Orthop. 2012 Apr;83(2):107-14. Epub 2012 Apr 11.
9. Hara T, Hayashi K, Nakashima Y, Kanemaru T, Iwamoto Y. The effect of hydroxyapatite coating on the bonding of bone to titanium implants in the femora of ovariectomised rats. J Bone Joint Surg Br. 1999 Jul;81(4):705-9.
10. Hayashi K, Fotovati A, Ali SA, Oda K, Oida H, Naito M. Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis. J Bone Joint Surg Br. 2005 Aug;87(8):1150-6.
11. Nakamura Y, Hayashi K, Abu-Ali S, Naito M, Fotovati A. Effect of preoperative combined treatment with alendronate and calcitriol on fixation of hydroxyapatitecoated implants in ovariectomized rats. J Bone Joint Surg Am. 2008 Apr;90(4): 824-32.
12. Ozawa S, Ogawa T, Iida K, Sukotjo C, Hasegawa H, Nishimura RD, Nishimura I. Ovariectomy hinders the early stage of bone-implant integration: histomorphometric, biomechanical, and molecular analyses. Bone. 2002 Jan;30 (1):137-43.
13. Duarte PM, César Neto JB, Gonçalves PF, Sallum EA, Nociti F. Estrogen deficiency affects bone healing around titanium implants: a histometric study in rats. Implant Dent. 2003;12(4):340-6.
14. Motohashi M, Shirota T, Tokugawa Y, Ohno K, Michi K, Yamaguchi A. Bone reactions around hydroxyapatite-coated implants in ovariectomized rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Feb;87(2):145-52.
15. Yamazaki M, Shirota T, Tokugawa Y, Motohashi M, Ohno K, Michi K, Yamaguchi A. Bone reactions to titanium screw implants in ovariectomized animals. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):411-8.
16. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003 Dec 1;22(23):6267-76.
17. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004 Mar 15;199(6):805-14.
18. Balemans W, EbelingM, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001 Mar 1;10(5):537-43.
19. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012 Oct;33(5):747-83. Epub 2012 Jun 20.
20. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009 Apr;24(4):578-88.
21. Tian X, Setterberg RB, Li X, Paszty C, Ke HZ, Jee WS. Treatment with a sclerostin antibody increases cancellous bone formation and bone mass regardless of marrow composition in adult female rats. Bone. 2010 Sep;47(3):529-33. Epub 2010 Jun 01.
22. Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimbimmobilization rat model. Bone. 2011 Feb;48(2):197-201. Epub 2010 Sep 17.
23. Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res. 2011 May;26(5):1012-21.
24. Cui L, Cheng H, Song C, Li C, Simonet WS, Ke HZ, Li G. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact. 2013 Jun;13(2):178-84.
25. McDonald MM, Morse A, Mikulec K, Peacock L, Yu N, Baldock PA, Birke O, Liu M, Ke HZ, Little DG. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res. 2012 Oct;30(10):1541-8. Epub 2012 Mar 27.
26. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010 Nov;25(11): 2412-8.
27. Virdi AS, Liu M, Sena K, Maletich J, McNulty M, Ke HZ, Sumner DR. Sclerostin antibody increases bone volume and enhances implant fixation in a rat model. J Bone Joint Surg Am. 2012 Sep 19;94(18):1670-80.
28. Liu S, Virdi AS, Sena K, Sumner DR. Sclerostin antibody prevents particleinduced implant loosening by stimulating bone formation and inhibiting bone resorption in a rat model. Arthritis Rheum. 2012 Dec;64(12):4012-20.
29. Irish J, Virdi AS, Sena K, McNulty MA, Sumner DR. Implant placement increases bone remodeling transiently in a rat model. J Orthop Res. 2013 May;31(5):800-6. Epub 2012 Dec 31.
30. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 Apr;11(2):116-28.
31. Ho JE, Barber TA, Virdi AS, Sumner DR, Healy KE. The effect of enzymatically degradable IPN coatings on peri-implant bone formation and implant fixation. J Biomed Mater Res A. 2007 Jun 1;81(3):720-7.
32. De Ranieri A, Virdi AS, Kuroda S, Healy KE, Hallab NJ, Sumner DR. Saline irrigation does not affect bone formation or fixation strength of hydroxyapatite/tricalcium phosphate-coated implants in a rat model. J Biomed Mater Res B Appl Biomater. 2005 Aug;74(2):712-7.
33. Liu S, Broucek J, Virdi AS, Sumner DR. Limitations of using micro-computed tomography to predict bone-implant contact and mechanical fixation. J Microsc. 2012 Jan;245(1):34-42. Epub 2011 Sep 15.
34. Iwaniec UT, Wronski TJ, Turner RT. Histological analysis of bone. Methods Mol Biol. 2008;447:325-41.
35. Sumner DR, Turner TM, Purchio AF, Gombotz WR, Urban RM, Galante JO. Enhancement of bone ingrowth by transforming growth factor-beta. J Bone Joint Surg Am. 1995 Aug;77(8):1135-47.
36. Sumner DR, Turner TM, Cohen M, Losavio P, Urban RM, Nichols EH, McPherson JM. Aging does not lessen the effectiveness of TGFbeta2-enhanced bone regeneration. J Bone Miner Res. 2003 Apr;18(4):730-6.
37. Liu S, Virdi AS, Sena K, Hughes WF, Sumner DR. Bone turnover markers correlate with implant fixation in a rat model using LPS-doped particles to induced implant loosening. J Biomed Mater Res A. 2012 Apr;100(4):918-28. Epub 2012 Jan 24.
38. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987 Dec;2(6):595-610.
39. Jee WS, Yao W. Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact. 2001 Mar;1(3):193-207.
40. Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA. The laboratory rat as an animal model for osteoporosis research. Comp Med. 2008 Oct;58(5):424-30.
41. Sumner DR, Turner TM, Urban RM, Virdi AS, Inoue N. Additive enhancement of implant fixation following combined treatment with rhTGF-beta2 and rhBMP-2 in a canine model. J Bone Joint Surg Am. 2006 Apr;88(4):806-17.
42. Lind M, Overgaard S, Soballe K, Nguyen T, Ongpipattanakul B, Bünger C. Transforming growth factor-b1 enhances bone healing to unloaded tricalcium phosphate coated implants: an experimental study in dogs. J Orthop Res. 1996;143:43-50.
43. Lind M, Overgaard S, Song Y, Goodman SB, Bünger C, Soballe K. Osteogenic protein 1 device stimulates bone healing to hydroxyapaptite-coated and titanium implants. J Arthroplasty. 2000 Apr;15(3):339-46.
44. Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res. 2010 May;25(5):948-59.
45. Gabet Y, Müller R, Levy J, Dimarchi R, Chorev M, Bab I, Kohavi D. Parathyroid hormone 1-34 enhances titanium implant anchorage in low-density trabecular bone: a correlative micro-computed tomographic and biomechanical analysis. Bone. 2006 Aug;39(2):276-82. Epub 2006 Apr 17.
46. Shirota T, Tashiro M, Ohno K, Yamaguchi A. Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats. J Oral Maxillofac Surg. 2003 Apr;61(4):471-80.
47. Eberhardt C, Schwarz M, Kurth AH. High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants. J Orthop Sci. 2005 Nov;10(6):622-6.
48. Kurth AH, Eberhardt C, Müller S, Steinacker M, Schwarz M, Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone. 2005 Aug;37(2):204-10.
49. Peter B, Pioletti DP, Läb S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli PY, Bouler JM, Gauthier O. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone. 2005 Jan;36(1):52-60. Epub 2004 Nov 23.
50. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 Jan 30;370(5):412-20. Epub 2014 Jan 01.
51. Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ. Short- and long-term effects of sclerostin antibody in an ovariectomized rat model [abstract]. In: Proceedings of the Annual Meeting of the American Society for Bone and Mineral Research; 2012 Oct 14. Minneapolis, MN: American Society for Bone and Mineral Research; 2012.